Cellix Bio Profile
Key Indicators
- Authorised Capital ₹ 23.10 Cr
as on 06-07-2024
- Paid Up Capital ₹ 22.47 Cr
as on 06-07-2024
- Company Age 10 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Revenue -44.30%
(FY 2021)
- Profit 41.77%
(FY 2021)
- Ebitda 40.54%
(FY 2021)
- Net Worth 16.05%
(FY 2021)
- Total Assets 50.53%
(FY 2021)
About Cellix Bio
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 23.10 Cr and a paid-up capital of Rs 22.47 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Cellix Bio Private Limited India is Nagendra Naidu as COMPANY SECRETARY. Achanna Valluri, Mahesh Kandula, Subramaniam Apparsundaram, and One other member serve as directors at the Company.
- CIN/LLPIN
U74900TG2014PTC094095
- Company No.
094095
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
21 May 2014
- Date of AGM
22 Dec 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Cellix Bio?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nagendra Naidu  | Company Secretary | 10-Jul-2023 | Current |
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Subramaniam Apparsundaram  | Director | 06-Oct-2017 | Current |
| Mahesh Kandula | Director | 01-Oct-2014 | Current |
| Achanna Valluri | Director | 21-May-2014 | Current |
| Sridhar Koganti | Whole-Time Director | Current |
Financial Performance and Corporate Structure Insights of Cellix Bio.
Cellix Bio Private Limited, for the financial year ended 2021, experienced significant reduction in revenue, with a 44.3% decrease. The company also saw a substantial improvement in profitability, with a 41.77% increase in profit. The company's net worth Soared by an impressive increase of 16.05%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Cellix Bio?
In 2020, Cellix Bio had a promoter holding of 97.41% and a public holding of 2.59%. The company had 1 Subsidiary. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Avaca Pharma Private LimitedActive 8 years 2 monthsMahesh Kandula and Sridhar Koganti are mutual person
Cellix Bio Pharma Private LimitedActive 4 years 10 monthsMahesh Kandula, Subramaniam Apparsundaram and 1 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Cellix Bio?
Unlock and access historical data on people associated with Cellix Bio, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Cellix Bio, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Cellix Bio's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
